A. Finn

发表

Effect of dose and food on the bioavailability of cefuroxime axetil.

A. Finn, A. Straughn, M. Meyer, 1987, Biopharmaceutics & drug disposition.

Opioid-induced constipation: rationale for the role of norbuprenorphine in buprenorphine-treated individuals

M. Camilleri, A. Finn, L. Webster, 2016, Substance abuse and rehabilitation.

Evaluation of the Tolerability of Switching Patients on Chronic Full μ-Opioid Agonist Therapy to Buccal Buprenorphine

A. Finn, L. Webster, E. Tzanis, 2016, Pain medicine.

Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers.

A. Finn, S. Bai, Q. Xiang, 2016, Clinical therapeutics.

Absorption and tolerability of fentanyl buccal soluble film (FBSF) in patients with cancer in the presence of oral mucositis

A. Finn, I. Tagarro, W. Hill, 2011, Journal of pain research.

Effects of ranitidine, given t.d.s., on intragastric and oesophageal pH in patients with gastrooesophageal reflux

A. Finn, W. Orr, A. Finn, 1991, Alimentary pharmacology & therapeutics.

Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.

L. Cubeddu, I. Hoffmann, A. Finn, 1990, The New England journal of medicine.

Ondansetron for the prevention of emesis induced by high‐dose cisplatin. A multi‐center dose‐response study

D. Gandara, A. Finn, D. Gandara, 1990, Cancer.

Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy.

L. Einhorn, A. Finn, C. Nagy, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo.

E. Perez, D. Gandara, A. Finn, 1992, Seminars in oncology.

Improving Drug Prescribing in a Primary Care Practice

W E Hammond, W J Taylor, M. Rodell, 1984, Medical care.

Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study

A. Finn, R. Rauck, J. North, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens.

L. Cubeddu, A. Finn, N. Fuenmayor, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and tolerability of buccal buprenorphine in opioid-experienced patients with moderate to severe chronic low back pain: results of a phase 3, enriched enrollment, randomized withdrawal study

A. Finn, Nathaniel Katz, E. Spierings, 2016, Pain.

Phenytoin: pharmacokinetics and clinical therapeutics.

C. Olanow, A. Finn, 1981, Neurosurgery.

Evaluation of the Single‐ and Multiple‐Dose Pharmacokinetics of Fentanyl Buccal Soluble Film in Normal Healthy Volunteers

A. Finn, I. Tagarro, L. Gever, 2010, Journal of clinical pharmacology.

Ondansetron (GR 38032F): A Novel Antiemetic Effective in Patients Receiving a Multiple‐Day Regimen of Cisplatin Chemotherapy

J. Hainsworth, A. Finn, G. Omura, 1991, American journal of clinical oncology.

Individualizing drug therapy: practical applications of drug monitoring

A. Finn, W. Taylor, 1981 .

Dose Proportionality and Pharmacokinetics of Fentanyl Buccal Soluble Film in Healthy Subjects

A. Finn, J. Stark, I. Tagarro, 2012, Clinical Drug Investigation.

Single-Dose Pharmacokinetics of Fentanyl Buccal Soluble Film

A. Finn, I. Tagarro, L. Gever, 2010, Pain medicine.

Formulation Selection and Pharmacokinetic Comparison of Fentanyl Buccal Soluble Film with Oral Transmucosal Fentanyl Citrate

A. Finn, I. Tagarro, L. Gever, 2009, Clinical drug investigation.

Intra- and Interindividual Variabilities in the Pharmacokinetics of Fentanyl Buccal Soluble Film in Healthy Subjects

A. Finn, A. Davies, I. Tagarro, 2012 .

Intra- and interindividual variabilities in the pharmacokinetics of fentanyl buccal soluble film in healthy subjects: a cross-study analysis.

A. Finn, A. Davies, I. Tagarro, 2011, Clinical drug investigation.

191) Dose linearity and absolute bioavailability of BEMA (BioErodible MucoAdhesive) fentanyl in healthy volunteers

A. Finn, J. Stark, N. Vasisht, 2008 .

Bioavailability and Metabolism of Prochlorperazine Administered via the Buccal and Oral Delivery Route

A. Finn, C. Lindley, R. Voyksner, 2005, Journal of clinical pharmacology.

Lignocaine disposition in blood in epilepsy.

A. Finn, P. Routledge, A. Barchowsky, 1981, British journal of clinical pharmacology.

Toxicity and side effects of ondansetron.

A. Finn, 1992, Seminars in oncology.

The effects of salicylate on the pharmacokinetics of phenytoin

C. Olanow, A. Finn, C. Prussak, 1981, Neurology.

The safety of BEMA (BioErodible MucoAdhesive) Fentanyl for breakthrough pain (BTP) in cancer patients

A. Finn, D. Blum, R. Kapoor, 2008 .

The timing of evening meal and ranitidine administration—effects on patterns of 24 hour intragastric acidity

A. Finn, M. Robinson, T. Wilson, 1988, Alimentary pharmacology & therapeutics.

Efficacy and tolerability of buccal buprenorphine in opioid-naive patients with moderate to severe chronic low back pain

A. Finn, R. Rauck, E. Tzanis, 2016, Postgraduate medicine.

Low-dose naloxone provides an abuse-deterrent effect to buprenorphine

A. Finn, L. Webster, Michael D. Smith, 2015, Journal of pain research.

Esophageal acid contact time and heartburn in acute treatment with ranitidine and metoclopramide.

A. Finn, W. Orr, J. Russell, 1990, American Journal of Gastroenterology.

Dose Proportionality and Pharmacokinetics of Fentanyl Buccal Soluble Film in Healthy Subjects : A Phase I, Open-Label, Three-Period, Crossover Study.

A. Finn, J. Stark, I. Tagarro, 2012, Clinical drug investigation.

Single-Dose Pharmacokinetics of Fentanyl

A. Finn, I. Tagarro, L. Gever, 2010 .